Skip to main content
Biocon drug receives DCGI nod for use in moderate to severe COVID-19 patients - The Indian Express 12-Jul-2020
Biocon drug receives DCGI nod for use in moderate to severe COVID-19 patients - The Indian Express
Biocon has repurposed Itolizumab, an anti-CD6 IgG1 monoclonal antibody launched in India in 2013 as ALZUMAb for treating chronic plaque psoriasis, for the treatment of CRS in moderate to severe ARDS patients due to COVID-19, the company said.
More...